Athira Pharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
LeonaBio, Inc. calls a Special Meeting to approve significant share issuances related to recent financing and a new equity incentive plan, crucial for advancing its strategic initiatives.
Athira Pharma, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.
Athira Pharma is asking stockholders to approve a reverse stock split and reduction in authorized shares to meet Nasdaq's minimum bid price requirement and potentially improve stock marketability.
Athira Pharma, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to Section 14(a) of the Securities Exchange Act of 1934.
DEF 14A: Athira Pharma Sets Date for 2024 Annual Stockholders Meeting, Proposes Officer Liability Amendment
Athira Pharma announces its 2024 annual meeting of stockholders to be held virtually on May 23, 2024, including proposals for director elections, auditor ratification, and an amendment to limit officer liability.